cyrilzakka/clinical-trials huggingface dataset:
Losartan Effects on Emotion-memory Interaction

The purpose of this study is to investigate whether a single dose of losartan (50 mg) can affect emotion-memory interaction in healthy humans and its underlying neural mechanisms.

Animal models and initial findings in humans suggest a role of the renin-angiotensin system in cognitive and emotional processes. Accumulating evidence demonstrates modulatory effects of the angiotensin antagonist losartan in the domains of memory and emotional processing. Against this background the present study aims to investigate the behavioral and neural effects of a single dose of losartan on emotional processing and emotion-memory integration in healthy subjects. In a double-blind, between-subject, placebo-controlled pharmaco-fMRI experiment, 60 male participants will be randomized to a single dose of losartan (50 mg) or placebo, and encode emotional pictures during fMRI (scheduled 90 minutes after drug administration). Then 24 hours post fMRI participants will finish a surprise recognition memory test to estimate the emotion effects on subsequent memory.

Eligibility Criteria:
Inclusion Criteria:

* Healthy subjects without past or current psychiatric or neurological disorders
* Right-handedness
* Normal or corrected-normal version

Exclusion Criteria:

* History of head injury
* Medical or psychiatric illness
* Hypertension
* General cardio-vascular alteration or diseases
* Allergy against medications
* Visual or motor impairments
* Claustrophobia
* Drug addiction
* Nicotine dependence
* FMRI contradictions
Comparing the Effect of Different Intracanal Dressing on Failed Root Canal Treated Cases on Periapical Healing

The goal of this clinical trial is to compare the effects of different intracanal medication between endodontic retreatment visits in previously failed root canal treatment patients (single root canal anteriors or premolars teeth). The main question it aims to answer are:

* Is natural and synthetic intracanal Medicament effective in reducing or complete healing of Periapical lesions or not? the researchers will compare the effect of different intracanal dressing including:
* nanocurcumin gel
* curcumin gel
* ciprofloxacin +ibuprofen gel
* calcium hydroxide Paste as control group in between the endodontic retreatment visits to see if these medicaments work well on periapical lesion healing this outcome measured by Cone beam CT at base and after 1 year follow up period


Eligibility Criteria:
Inclusion Criteria:

* Medically free Patients
* both sex includes male and females
* Patients age between 20-60
* Patients agreement positively to share in the study
* patient able to sign informed consent
* on clinical and radiographic examinations, the included teeth maxillary and mandibular single root canal anteriors or premolars suffering from failed endodontic treatment with periapical lesion

Exclusion Criteria:

* badly broken down teeth indicated for extraction or with difficult isolation
* teeth with former procedural errors as ledge, perforation or instrument separation
* Medically compromised patients
* patients with history of receiving antibiotics within a month before starting study
* periodontally affected teeth by pocket depth \& \> 4mm
Stereotactic Radiotherapy in Association With Immunotherapy for the Treatment of NSCLC Brain Metastases

The study's primary objective is the evaluation of toxicities reported during RS or HFSRT in patients with brain metastases from NSCLC undergoing immunotherapy (Safety), with particular reference to the rate of symptomatic radionecrosis and intralesional hemorrhage. Others primary objectives of the study are the Feasibility and the intracranial control of the disease, both local (site radiotherapy treatment) and at a distance (intracranial, but at a distance from the site of the disease treated with stereotaxic radiotherapy). The secondary objectives concern quality assessment of life of the patients under study (Quality Of Life, QoL).


Eligibility Criteria:
Inclusion Criteria:

* Age\> 18 years

  * Ability to express informed consent
* Histological or cytological diagnosis (possibility of PDL-1 determination) of NSCLC
* - Brain metastases up to a maximum of 10 and all treated with RS or Hypofractionated stereotactic radiotherapy (3 to 5 fractions)
* Brain disease assessable according to iRANO criteria
* Radiation therapy on brain metastases within 4 weeks before or after infusion of immunotherapy in the following settings
* brain metastases at initio brain metastases treated with RS + 1st line therapy
* Brain metastases as I progression after I line of systemic therapy CHT, IT or CHTIT regardless of whether or not the same line is continued (treatment Beyond progression) or shift to the next line;
* Brain metastases as II progression after II line of systemic therapy (CHT, IT) regardless of whether it is continued or not of the same line (treatment beyond progression) or shift to the next line.
* Diagnostic brain MRI for brain metastases within one month of treatment stereotactic

Esclusion criteria:

* Life expectancy of less than 6 months (calculated with GPA score \<2)
* Performance Status\> 2
* Previous radiotherapy treatment at the brain site
* Contraindication to MRI of the brain with contrast medium
* Presence of a number of intracranial metastases\> 10
* Inability to express informed consent
* Infusion of immunotherapy more than 4 weeks before and after radiotherapy
* Impossibility of recording times and dosages of administration of steroid therapy
* Ineligibility for immunotherapy treatment

Exclusion Criteria:

-
Genetic Differences in Propofol Pharmacodynamics in Children

Propofol is an extensively utilized intravenous sedative and general anesthetic. However, propofol has a narrow therapeutic index, and this means that there is only a small difference in the dose required to produce loss of consciousness and the dose required to produce potentially life-threatening effects such as loss of protective airway reflexes and cessation of spontaneous breathing. Moreover, there is substantial variation between individuals in the doses required to achieve these pharmacodynamic endpoints.

Given the inexorable rise in demand for pediatric sedation and the increasing use of propofol in sedation protocols by non-anaesthesiologists, the purpose of this study is to refine the propofol dosing recommendations to account for pharmacogenomic variability to make procedural sedation safer for children. Experienced users already adjust for age and body weight. This study may enable further refinements according to sex and - novelly - ancestry.

Hypothesis:

The investigators hypothesize that examination of genome-wide association study (GWAS) findings will enable the investigators to provide pharmacogenomic insights into clinically observed - and, with this study, quantified - differences in propofol requirements for loss of consciousness (LOC) and apnea in children. It is further hypothesized that the distribution of allelic variants in these pharmacogenes may differ between children of different genomic ancestry.

Objectives:

Primary: (i) To describe and quantify doses of propofol required to produce loss of consciousness and apnea in children of differing ages, sex and self-identified countries of origin. (ii) To identify genomic associations that may explain variability, and generate hypotheses for further study. (iii) To identify genomic ancestry and examine how pharmacogene allele variants that may explain the findings of (i) above are distributed across genomic ancestries.

Secondary: To examine the correlation between self-identified countries of family origin and genomic ancestry.

Methods:

Prospective, non-randomized, single cohort study of two pharmacodynamic endpoints (loss of consciousness and apnea), in children requiring propofol anesthesia, with subsequent genome-wide association study (GWAS) and principal component analysis (PCA) to examine, respectively, pharmacogenomic explanations for pharmacodynamic variability and genomic ancestry.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 3 to ≤ 18
* ASA physical status classification I-III
* Intravenous induction resulting in apnea clinically appropriate and indicated

Exclusion Criteria:

* Age \< 3 or \>18
* ASA physical status IV-V
* Propofol induction to apnea not indicated or feasible
* Sedative premedication
* Severe neurological impairment, expected to reduce propofol requirement as judged by the clinical experience of the anaesthetist
* Weight \<3%ile or \>97%ile for age